The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma
Open accessAbstract
Immune checkpoint inhibitors (ICIs) with nivolumab and pembrolizumab are promising agents for advanced hepatocellular carcinoma (HCC) but lack of effective biomarkers. We aimed to investigate the potential predictors of response and factors associated with overall survival (OS) for ICI treatment in unresectable HCC patients. Ninety-five patients who received nivolumab or pembrolizumab for unresectable HCC were enrolled for analyses. Radiologic evaluation was based on RECIST v1.1. Factors associated with outcomes were analyzed. Of 90 patients with evaluable images, the objective response rate (ORR) was 24.4%. Patients at Child–Pugh A or received combination treatment had higher ORR. Early alpha-fetoprotein (AFP) >10% reduction (within 4 weeks) was the only independent predictor of best objective response (odds ratio: 7.259, p = 0.001). For patients with baseline AFP ≥10 ng/mL, significantly higher ORR (63.6% vs. 10.2%, p < 0.001) and disease control rate (81.8% vs. 14.3%, p < 0.001) were observed in those with early AFP reduction than those without. In addition, early AFP reduction and albumin-bilirubin (ALBI) grade or Child–Pugh class were independent factors associated with OS in different models. In conclusion, a 10-10 rule of early AFP response can predict objective response and survival to ICI treatment in unresectable HCC. ALBI grade and Child–Pugh class determines survival by ICI treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Erdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,656
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,974
Cited by
Sorted by citations
Biomarkers for immunotherapy of hepatocellular carcinoma
Greten, T. F., Villanueva, A., Korangy, F., Ruf, B., Yarchoan, M., Ma, L., Ruppin, E., & Wang, X. W. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00816-4 · Cited by 227
Demirtaş, C. Ö., D’Alessio, A., Rimassa, L., Sharma, R., & Pinato, D. J. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100347 · Cited by 230
Lee, P.-C., Wu, C.-J., Hung, Y.-W., Lee, C. J., Chi, C.-T., Lee, I.-C., Yu-Lun, K., Chou, S.-H., Luo, J.-C., Hou, M.-C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004779 · Cited by 217
Self-citationShao, Y., Wang, S.-Y., Lin, S., Chen, K.-Y., Tseng, J., Ho, M., Lee, R., Liang, P., Liao, L., Huang, K., et al. (2020) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2020.10.031 · Cited by 114
Self-citationProgress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
Lei, Y., Li, X., Huang, Q., Zheng, X., & Liu, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.617335 · Cited by 94
Lee, P., Chao, Y., Chen, M., Lan, K., Lee, I., Hou, M., & Huang, Y. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001072 · Cited by 89
Self-citationImmune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma
Xie, E., Yeo, Y. H., Scheiner, B., Zhang, Y., Hiraoka, A., Tantai, X., Fessas, P., de Castro, T., D’Alessio, A., Fulgenzi, C. A. M., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.3284 · Cited by 97
An, Y., Wu, Z., Wang, N., Yang, Z., Li, Y., Xu, B., & Sun, M. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02404-x · Cited by 82
Pinato, D. J., Kaneko, T., Saeed, A., Pressiani, T., Kaseb, A. O., Wang, Y., Szafron, D., Jun, T. W., Dharmapuri, S., Naqash, A. R., et al. (2020) · Cancers · doi:10.3390/cancers12071862 · Cited by 77
Self-citationImmunotherapy for hepatocellular carcinoma: Recent advances and future targets
Yu, S. J. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108387 · Cited by 70
Zhang, L., Feng, J., Kuang, T., Chai, D., Qiu, Z., Deng, W., Dong, K., Zhao, K., & Wang, W. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110019 · Cited by 65
Fessas, P., Kaseb, A. O., Wang, Y., Saeed, A., Szafron, D., Jun, T. W., Dharmapuri, S., Naqash, A. R., Muzaffar, M., Navaid, M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001033 · Cited by 60
Self-citationChoi, W., Lee, D., Shim, J. H., Kim, K. M., Lim, Y., Lee, H. C., Yoo, C., Park, S. R., Ryu, M., Ryoo, B., et al. (2020) · Cancers · doi:10.3390/cancers12071968 · Cited by 59
Recent advances in immunotherapy for hepatocellular carcinoma
Khan, A. A., Liu, Z., & Xu, X. (2021) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2021.06.010 · Cited by 56
Hayakawa, Y., Tsuchiya, K., Kurosaki, M., Yasui, Y., Kaneko, S., Tanaka, Y., Ishido, S., Inada, K., Kirino, S., Yamashita, K., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01185-4 · Cited by 55
Wu, C.-J., Lee, P., Hung, Y., Lee, C.-J., Chi, C., Lee, I., Hou, M., & Huang, Y. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03185-6 · Cited by 42
Self-citationMon, H.-C., Lee, P., Hung, Y.-P., Hung, Y., Wu, C.-J., Lee, C.-J., Chi, C., Lee, I., Hou, M., & Huang, Y. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.07.018 · Cited by 42
Self-citationAtezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma
Cheon, J., Kim, H., Kim, H. S., Kim, C. G., Kim, I. H., Kang, B., Kim, C., Jung, S., Ha, Y., & Chon, H. J. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221148541 · Cited by 36
Hung, H., Lee, J., Wang, Y., Cheng, C., Wu, T., Lee, C., Wu, T.-J., Chou, H., Chan, K., & Lee, W. (2021) · Cancers · doi:10.3390/cancers13071607 · Cited by 36
Self-citationSung, P. S., Jang, J. W., Lee, J., Lee, S. K., Lee, H. L., Yang, H., Nam, H. C., Lee, S. W., Bae, S. H., Choi, J. Y., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01043 · Cited by 33
Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
He, Y., Lu, M., Che, J., Chu, Q., Zhang, P., & Chen, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.716844 · Cited by 34
Kim, H. I., Lim, J., & Shim, J. H. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03727-y · Cited by 32
Reappraisal of the Role of Alkaline Phosphatase in Hepatocellular Carcinoma
Huang, C.-W., Wu, T., Hsu, H.-Y., Pan, K., Lee, C., Chong, S.-W., Huang, S.-F., Lin, S., Yu, M., & Chen, S. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12040518 · Cited by 30
Self-citationTeng, W., Lin, C., Lin, P.-T., Hsieh, Y., Ho, M.-M., Hsieh, C.-H., Lin, C., & Lin, S. (2022) · Journal of Hepatology · doi:10.1016/s0168-8278(22)01098-4 · Cited by 30
Yu, J., Li, M., Ren, B., Cheng, L., Wang, X., Ma, Z., Yong, W. P., Chen, X., Wang, L., & Goh, B. C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1261575 · Cited by 31
Immunotherapy in older patients with hepatocellular carcinoma
Lyu, N., Yi, J., & Zhao, M. D. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.11.024 · Cited by 29
Tsai, H., Han, M., Lin, Y., Chang, T., Chen, C., Cheng, P., Chuang, C., Wu, I., Chen, P., Kang, J., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02845-9 · Cited by 27
Mishra, G., Majeed, A., Dev, A. T., Eslick, G. D., Pinato, D. J., Izumoto, H., Hiraoka, A., Huo, T., Liu, P., Johnson, P. J., et al. (2022) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-022-00832-0 · Cited by 27
Liu, B., Shang, X., Shi, J., Cui, G., Li, X., & Wang, N.-Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.807189 · Cited by 25
Pallozzi, M., Tommaso, N. D., Maccauro, V., Santopaolo, F., Gasbarrini, A., Ponziani, F. R., & Pompili, M. (2022) · Cancers · doi:10.3390/cancers14194631 · Cited by 27
Pan, H., Zhou, L., Cheng, Z., Zhang, J., Shen, N., Ma, H., Li, Y., Jin, R., Zhou, W., Wu, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53704-5 · Cited by 26
Chen, S., Huang, Y., Chen, M., Hung, Y., Lee, R., Shao, Y., & Chao, Y. (2022) · BMC Cancer · doi:10.1186/s12885-022-09173-4 · Cited by 24
Self-citationKwee, S. A., & Tiirikainen, M. (2021) · Hepatoma Research · doi:10.20517/2394-5079.2020.124 · Cited by 24
Yau, T. C. C., Tai, D. W.-M., Chan, S. L., Huang, Y., Choo, S. P., Hsu, C., Cheung, T. T., Lin, S., Yong, W. P., Lee, J. J. X., et al. (2022) · Liver Cancer · doi:10.1159/000525582 · Cited by 23
Self-citationPsilopatis, I., Damaskos, C., Garmpi, A., Sarantis, P., Koustas, E., Antoniou, E., Dimitroulis, D., Kouraklis, G., Karamouzis, M. V., Vrettou, K., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032685 · Cited by 22
Radiation-induced liver disease in the era of SBRT: a review
de la Pinta, C. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1814744 · Cited by 22
Teng, W., Lin, C., Ho, M.-M., Lui, K., Wang, S., Hsu, C., & Lin, S. (2021) · PubMed Central · Cited by 22
Kawashima, A., Yamamoto, Y., Sato, M., Nakata, W., Kakuta, Y., Ishizuya, Y., Yamaguchi, Y., Yamamoto, A., Yoshida, T., Takayama, H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-00509-x · Cited by 23
Immunotherapy-Based Treatments of Hepatocellular Carcinoma: AJR Expert Panel Narrative Review
Cannella, R., Lewis, S. C., da Fonseca, L. G., Ronot, M., & Rimola, J. (2022) · American Journal of Roentgenology · doi:10.2214/ajr.22.27633 · Cited by 21
Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?
Lee, C., Chan, S., & Chon, H. (2022) · Cancers · doi:10.3390/cancers14133213 · Cited by 19
Self-citationDing, H., Liu, J., Wang, C., & Su, Y. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01520-4 · Cited by 19
Zhu, H., Feng, J.-K., Xiang, Y., Wang, K., Zhou, L.-P., Liu, Z., Cheng, Y., Shi, J., Guo, W., & Cheng, S. (2023) · BMC Cancer · doi:10.1186/s12885-023-11003-0 · Cited by 19
Hsu, W., Chuang, P., Chen, C., Wang, H., Tsai, M.-H., Su, W., Chen, H., Yang, C., Lin, C., Huang, G., et al. (2020) · PubMed Central · Cited by 18
Hsu, W., Wang, H., Chen, C., Lai, H., Chuang, P., Tsai, M.-H., Su, W., Chen, H., Chu, C., Chou, J., et al. (2021) · PubMed Central · Cited by 18
Self-citationChi, C., Lee, I., Lee, R., Hung, Y., Su, C., Hou, M., Chao, Y., & Huang, Y. (2021) · Cancers · doi:10.3390/cancers13174325 · Cited by 17
Self-citationHan, C., Tian, B., Yan, L., Ding, Z., Liu, H., Mao, X., Tian, J.-C., Xue, J.-S., Tan, S., Dong, Z., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03390-x · Cited by 17
Zhou, X., Cao, J., Topatana, W., Xie, T., Chen, T., Hu, J., Li, S., Juengpanich, S., Lu, Z., Zhang, B., et al. (2023) · Immunotherapy · doi:10.2217/imt-2022-0168 · Cited by 17
Self-citationSuzuki, K., Yasui, Y., Tsuchiya, K., Matsumoto, H., Yamazaki, Y., Uchihara, N., Tanaka, Y., Miyamoto, H., Yamada‐Shimizu, M., Keitoku, T., et al. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16532 · Cited by 17
Hiraoka, A., Tanizawa, Y., Huang, Y., Cai, Z., & Sakaguchi, S. (2021) · Drugs - Real World Outcomes · doi:10.1007/s40801-021-00245-8 · Cited by 17
Self-citationThe rapidly evolving landscape of HCC: Selecting the optimal systemic therapy
Zanuso, V., Rimassa, L., & Braconi, C. (2023) · Hepatology · doi:10.1097/hep.0000000000000572 · Cited by 16
Hwang, S. Y., Zavareh, M. S. R., Attia, A. M., Kaymen, E. A., Tran, N. H., Abou‐Alfa, G. K., Parikh, N. D., Singal, A. G., & Yang, J. D. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003546 · Cited by 15
Tian, B., Yan, L., Ding, Z., Liu, H., Han, C., Meng, G.-X., Xue, J.-S., Dong, Z., Yan, Y., Hong, J., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109519 · Cited by 15
Wang, X., Yang, X., Wang, J., Dong, C., Ding, J., Wu, M., Wang, Y., Ding, H., Zhang, H., Sang, X., et al. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s401647 · Cited by 14
Hsu, P., Cheng, T., Chuang, S., Chang, W., Liang, P., Hsu, C., Wei, Y., Jang, T., Yeh, M., Huang, C., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4430 · Cited by 13
Self-citationThe immune landscape of hepatocellular carcinoma‑where we are? (Review)
Gryziak, M., Woźniak, K., Kraj, L., Róg, L., & Stec, R. (2022) · Oncology Letters · doi:10.3892/ol.2022.13530 · Cited by 14
Lu, L., Zheng, P., Pan, Y., Huang, S., Shao, E., Huang, Y., Wang, X., Chen, Y., Cuo, G., Yang, H., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02334-7 · Cited by 13
Self-citationPark, J. E., Jo, J., Youk, J., Kim, M., Yoon, S. H., Keam, B., Kim, T. M., & Kim, D. (2023) · Insights into Imaging · doi:10.1186/s13244-023-01532-4 · Cited by 14
Ji, Z., Li, J., Zhang, S., Jia, Y., Zhang, J., & Guo, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1480520 · Cited by 13
Hsu, W., Hsu, S.-C., Chen, T.-H., Lin, C., Lin, Y., Chang, Y., Wang, H., Liao, Y.-M., Lai, H., & Peng, C. (2022) · Cancers · doi:10.3390/cancers14205083 · Cited by 13
Kinami, T., Amioka, K., Kawaoka, T., Uchikawa, S., Yamasaki, S., Kosaka, M., Johira, Y., Yano, S., Naruto, K., Ando, Y., et al. (2023) · Cancers · doi:10.3390/cancers15082304 · Cited by 13
Tian, B., Yan, L., Ding, Z., Liu, H., Meng, G.-X., Xue, J.-S., Han, C., Dong, Z., Hong, J., Chen, Z., et al. (2022) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2022.2156859 · Cited by 12
Immunosenescence and immunotherapy in elderly patients with hepatocellular carcinoma
Zhang, D., Zhu, Y., Shen, Z., Ma, S., Liu, S., & Lu, Z. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.02.010 · Cited by 12
Peng, T., Wu, C., Chang, S.-Y., Chen, Y.-C., Wu, T., & Hsu, C. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109223 · Cited by 13
Tian, B., Yan, L., & Liang, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1695861 · Cited by 11
Lee, I., Chao, Y., Lee, P., Chen, S., Chi, C., Wu, C.-J., Wu, K., Hou, M., & Huang, Y. (2022) · Cancers · doi:10.3390/cancers14082014 · Cited by 11
Self-citationXu, H., Cao, D., Zheng, Y., Zhou, D., Chen, X., Lei, J.-J., Ge, W., & Xu, X. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108135 · Cited by 10
Cammarota, A., Zanuso, V., Pressiani, T., Personeni, N., & Rimassa, L. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s268293 · Cited by 10
Liu, S., Li, Z., Lin, J., Ke, L., & Hua, Y. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70427 · Cited by 11
Cerrito, L., Ainora, M. E., Mosoni, C., Borriello, R., Gasbarrini, A., & Zocco, M. A. (2022) · Cancers · doi:10.3390/cancers14194647 · Cited by 9
Liu, Y., Pan, J., Gao, F., Xu, W., Li, H., & Qi, X. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02371-3 · Cited by 12
Ueno, M., Kosaka, H., Iida, H., Ida, Y., Aoi, K., Mori, H., Miyamoto, A., Nishida, Y., Hayami, S., Kawai, M., et al. (2023) · Oncology · doi:10.1159/000531317 · Cited by 9
Chen, S., Ho, H., Liu, C., Hung, Y., Chiang, N., Chen, M., Chao, Y., & Yang, M.-H. (2025) · BMC Cancer · doi:10.1186/s12885-025-13568-4 · Cited by 9
Self-citationHe, P., Wan, H., Wan, J., Jiang, H., Yu, Y., Xie, K., & Wu, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1015527 · Cited by 9
Kournoutas, I. A., Marell, P. S., Gile, J. J., Peersen, A. F., Shah, P., VanDommelen, K., Kamath, S. D., Gupta, G., Akce, M., Yang, J. D., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf286 · Cited by 8
Cheng, K.-L., Cheng, Y., Chan, C., & Wang, C. (2023) · Digestive Diseases and Sciences · doi:10.1007/s10620-023-07984-4 · Cited by 8
Hsu, Y.-C., Lin, P., Teng, W., Hsieh, Y., Chen, W., Su, C., Wang, C., Chai, P., Lin, C., Lin, C.-Y., et al. (2024) · Cancers · doi:10.3390/cancers16203458 · Cited by 8
Kuo, H., Han, M., Liao, C., Lin, Y., Wang, C.-T., Chen, S., Chang, T., Chen, P., Lin, S., Chen, C., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112263 · Cited by 7
Self-citationIshizuya, Y., Kawashima, A., Horibe, Y., Yamamoto, A., Tani, M., Yoshimura, A., Liu, Y., Nesrine, S., Oka, T., Okuda, Y., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-86212-7 · Cited by 6
Zou, H., Lei, Q., Yan, X., Lai, Y., Ung, C. O. L., & Hu, H. (2022) · Cancers · doi:10.3390/cancers15010260 · Cited by 6
Chan, K., Lai, Y., Hung, H., Lee, J., Cheng, C., Wang, Y., Wu, T., Lee, C., Wu, T.-J., Chou, H., et al. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s393964 · Cited by 6
Self-citationZeng, Y., Gu, J., He, W., & Luo, J. (2025) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848251387501 · Cited by 5
Zhang, Y., Shen, H., Zheng, R., Sun, Y., Xie, X., Lu, M., Liu, B., & Huang, G. (2023) · Cancers · doi:10.3390/cancers15215131 · Cited by 5
Cowzer, D., Chou, J. F., Walch, H. S., Keane, F., Khalil, D. N., Shia, J., Do, R. K. G., Yarmohammadi, H., Erinjeri, J. P., Dika, I. E., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae110 · Cited by 5
Swaroop, S., Biswas, S., Mehta, S., Aggarwal, A., Arora, U., Agarwal, S., Chavan, A., Nayak, B., & Shalimar, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14031034 · Cited by 5
Hsu, W., Lai, H., Chen, C., Wang, H., Chuang, P., Tsai, M.-H., Chen, S., Chu, C., Su, W., Chou, J., et al. (2023) · PubMed Central · Cited by 5
Self-citationJeng, L., Wang, J. C. K., & Teng, C. (2023) · Journal of Cancer · doi:10.7150/jca.90128 · Cited by 5
Huang, K.-W., Lee, P., Chao, Y., Su, C., Lee, I., Lan, K., Chu, C., Hung, Y., Chen, S., Hou, M., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221099401 · Cited by 4
Self-citationLee, S., Yang, S., & Lee, T. (2024) · Gastroenterology Research · doi:10.14740/gr1684 · Cited by 4
Ding, X., Zhang, K., & Xu, M. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.21.04282-8 · Cited by 4
Lee, P., Wu, C.-J., Lee, I., Lee, C.-J., Hou, M., & Huang, Y. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101491 · Cited by 3
Self-citationRajappa, S. J., Rau, K., Dattatreya, P. S., Ramaswamy, A., Fernandes, P., Pruthi, A., Cheng, R., Lukanowski, M., & Huang, Y. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i6.1074 · Cited by 3
Self-citationColloca, G. A., & Venturino, A. (2024) · Cancer · doi:10.1002/cncr.35199 · Cited by 3
Tian, J., Pan, S., Wang, Y., Yu, Y., Wang, S., Shen, Y., Yang, L., Liu, X., Qiu, Q., Luan, J., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12122769 · Cited by 2
Wonglhow, J., Sunpaweravong, P., Sathitruangsak, C., & Dechaphunkul, A. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14040403 · Cited by 2
Immunotherapy for hepatocellular carcinoma: The challenge of biomarker studies
Lee, I. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000458 · Cited by 2
Self-citationShan, X., Zhang, M., Lin, H., Zhu, M., & Li, M. (2021) · Trends in Oncology · doi:10.37155/2717-5278-2021-03-02-1 · Cited by 1
Right inguinal metastasis from hepatocellular carcinoma
Fu, C., Lei, H.-J., Wang, L., Wei, C., Su, C., Hou, M., Huang, Y., & Lee, P. (2021) · Advances in digestive medicine · doi:10.1002/aid2.13277 · Cited by 1
Self-citationGray, S., Lamarca, Á., McNamara, M. G., Edeline, J., Hanley, K. P., Valle, J. W., & Hubner, R. A. (2022) · Liver Cancer International · doi:10.1002/lci2.62 · Cited by 1
Lin, P.-T., Teng, W., Chen, W.-T., Su, C., Hsieh, Y., Lin, C., Lin, C., & Lin, S. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06381-w · Cited by 1
Ding, H., Liu, J., Wang, C., & Su, Y. (2020) · Figshare · doi:10.6084/m9.figshare.12900428
Metadata
- Authors
- Lee, P.-C., Chao, Y., Chen, M.-H., Lan, K.-H., Lee, C.-J., Lee, I.-C., Chen, S.-C., Hou, M.-C., & Huang, Y.-H.
- Affiliations
- Taipei Veterans General Hospital (TW)
- Corresponding author
- Chao, Yee
- Huang, Yi-Hsiang
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2020-01-11
- Volume
- 12
- Issue
- 1
- Pages
- 182
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC7017111
- OpenAlex
- W2999675465
- Cited by
- 105
- References
- 42
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 10 · 2023: 21 · 2022: 27 · 2021: 20 · 2020: 12
- FWCI
- 11.76
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Ministry of Science and Technology, Taiwan (MOST108-2628-B075-006, MOST 108-)
- Taipei Veterans General Hospital (V109C‐048)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- hepatocellular carcinoma, immune checkpoint inhibitors, nivolumab, pembrolizumab, predictive biomarkers, alpha-fetoprotein, objective response rate, overall survival, albumin-bilirubin grade, Child-Pugh score, combination therapy, RECIST 1.1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
